Table 1 Baseline characteristics of patients at the initiation of first-line EGFR-TKIs.
Variables | All (N = 138) | MINO + (N = 32) | MINO – (N = 106) | P value |
|---|---|---|---|---|
Age, years | 70 (23–88) | 68 (39–85) | 71 (23–88) | 0.078 |
Male | 36 (26.1) | 10 (31.2) | 26 (24.5) | 0.49 |
Smoker | 37 (26.8) | 11 (35.5) | 26 (24.8) | 0.26 |
Adenocarcinoma | 135 (97.8) | 31 (96.9) | 104 (98.1) | 0.55 |
EGFR mutation | ||||
Ex19 deletion | 62 (44.9) | 16 (50) | 46 (43.4) | 0.64 |
Ex21 L858R | 62 (44.9) | 12 (37.5) | 50 (47.2) | |
Minor mutation | 14 (10.1) | 4 (12.5) | 10 (9.4) | |
First-line EGFR-TKIs | ||||
Gefitinib | 49 (35.5) | 6 (18.8) | 43 (40.6) | < 0.001 |
Erlotinib | 34 (24.6) | 12 (37.5) | 22 (20.8) | |
Afatinib | 17 (12.3) | 12 (37.5) | 5 (4.7) | |
Osimertinib | 38 (27.5) | 2 (6.2) | 36 (34.0) | |
Combination of first-line EGFR-TKI and VEGF or VEGFR inhibitor | 0 (0) | 0 (0) | 0 (0) | 1.0 |
High expression of PD-L1 | 7 (5.1) | 2 (6.2) | 5 (4.7) | 0.14 |
Recurrence after surgery | 56 (40.6) | 11 (34.4) | 45 (42.5) | 0.14 |
Days from 1st EGFR-TKI administration to minocycline administration, days | 14.5 (0–1133) | |||
Duration of minocycline administration, days | 388.5 (33–2396) | |||
